VEGFA and neoplasm: Specifically, tumor xenografts were generated by subcutaneously injecting the RAS-mutant CRC mouse cell line CT26 into Balb/c mice, which were then treated with vehicle alone, VPA, suboptimal doses of CHT with an anti-VEGF antibody, or VPA plus CHT and anti-VEGF, as illustrated in Supplementary Fig. 10a.